journal
MENU ▼
Read by QxMD icon Read
search

Pediatric Blood & Cancer

journal
https://www.readbyqxmd.com/read/27905689/development-of-quality-indicators-for-transition-from-pediatric-to-adult-care-in-sickle-cell-disease-a-modified-delphi-survey-of-adult-providers
#1
Amy E Sobota, Nishita Shah, Jennifer W Mack
BACKGROUND: Transition from pediatric to adult care is a vulnerable time for young adults with sickle cell disease (SCD); however, improvements in transition are limited by a lack of quality indicators. The purpose of this study was to establish quality indicators for transition in SCD and to determine the optimal timing between the final pediatric visit and the first adult provider visit. PROCEDURE: We conducted a modified Delphi survey to reach a consensus on which quality indicators are most important for a successful transition...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905688/liposomal-doxorubicin-effective-treatment-for-pediatric-desmoid-fibromatosis
#2
Prasanna Ananth, Annette Werger, Stephan Voss, Carlos Rodriguez-Galindo, Katherine A Janeway
Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression-free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905687/ommaya-reservoir-off-duty-causing-major-late-onset-complications-in-a-child-with-medulloblastoma
#3
LETTER
Janina H Walker, Annette Hackenberg, Oliver Bozinov, Christoph Berger, Ianina Scheer, Michael A Grotzer, Nicolas U Gerber
No abstract text is available yet for this article.
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905686/lymphoblasts-with-auer-rod-like-inclusions-in-a-case-of-paediatric-b-lymphoblastic-leukemia
#4
LETTER
Anurag Gupta, G Krishna Reddy, Nagaraju Nalla, Manu Goyal
No abstract text is available yet for this article.
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905684/the-effect-of-maternal-and-infant-factors-on-cord-blood-yield
#5
REVIEW
Seyed Hadi Mousavi, Saeid Abroun, Morteza Zarrabi, Mona Ahmadipanah
Umbilical cord blood (CB) can be used as an alternative hematopoietic stem cell source for transplantation in hematological malignancy and blood disorders. The success of transplantation is highly related to the levels of total nucleated cell and CD34(+) cell counts. The evaluation of optimal conditions can decrease the rate of graft rejection due to low cell count and increases the quality of CB units (CBUs) in the blood bank and the success rate of engraftment. To this end, we review the maternal and infant parameters affecting the quality and quantity of CBUs...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905683/prolonged-neutropenia-due-to-antihuman-neutrophil-antigen-2-cd177-antibody-after-bone-marrow-transplantation
#6
Taizo Wada, Satoshi Miyamoto, Hiroyuki Okamoto, Yusuke Matsuda, Tomoko Toma, Kohsuke Imai, Masatoshi Takagi, Tomohiro Morio, Akihiro Yachie
We describe a patient who presented with prolonged neutropenia due to anti-human neutrophil antigen (HNA)-2 (CD177) antibody after allogeneic bone marrow transplantation. A granulocyte immunofluorescence test showed bimodal expression of antineutrophil antibody that resulted from specific binding of anti-HNA-2 to CD177(+) neutrophils from healthy donors. The patient did not respond to granulocyte colony stimulating factor, which is able to upregulate CD177 expression on neutrophils. The low percentage of CD177(+) cells in the few remaining neutrophils supports the possibility of elimination of CD177-upregulated neutrophils...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905682/a-survey-of-pediatric-hematology-oncology-specialists-regarding-management-of-central-line-associated-venous-thrombosis
#7
Char M Witmer, Emily Sauck, Leslie J Raffini
Central venous catheters (CVCs) account for the largest proportion of thrombotic events in pediatric patients. Questions remain regarding adequate treatment and prevention methods. We surveyed pediatric hematology/oncology specialists, using hypothetical cases to assess management strategies for acute CVC thrombosis and secondary prevention. Survey respondents varied in the use of the thrombophilia evaluation (33.3%, 41/123) and duration of treatment (6 weeks: 54.1%, 66/122). Secondary CVC prophylaxis was utilized by 36...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905681/childhood-immune-thrombocytopenia-a-nationwide-cohort-study-on-condition-management-and-outcomes
#8
Lamiae Grimaldi-Bensouda, Clémentine Nordon, Thierry Leblanc, Lucien Abenhaim, Slimane Allali, Corinne Armari-Alla, Claire Berger, Mary-France Courcoux, Fanny Fouyssac, Cécile Guillaumat, Corinne Guitton, Philippe Le Moine, Françoise Mazingue, Corinne Pondarré, Caroline Thomas, Marlène Pasquet, Yves Perel, Guy Leverger, Nathalie Aladjidi
OBJECTIVES: Nationwide prospective cohort study exploring (i) the factors associated with treatment initiation (vs. watchful waiting) in children with primary immune thrombocytopenia (ITP) followed in routine clinical practice and (ii) the predictors of chronicity at 12 months. PROCEDURE: Between 2008 and 2013, 23 centers throughout France consecutively included 257 children aged 6 months-18 years and diagnosed with primary ITP over a 5-year period. Data on ITP clinical features along with medical management were collected at baseline and 12 months...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905680/the-burden-of-childhood-cancer-in-mexico-implications-for-low-and-middle-income-countries
#9
REVIEW
Roberto Rivera-Luna, Marta Zapata-Tarres, Jaime Shalkow-Klincovstein, Liliana Velasco-Hidalgo, Alberto Olaya-Vargas, Nicole Finkelstein-Mizrahi, Rocío Cárdenas-Cardós, Marco R Aguilar-Ortiz
In Mexico, childhood cancer incidence and mortality have increased in the last decade. Through government actions since 2005, the Popular Medical Insurance (PMI) program for childhood cancer was created. The objective of PMI was to offer early cancer diagnosis, standardized treatment regimens, and numerous pediatric oncology residency programs. It has also accredited 55 national hospitals for the care of these children. Current problems still present under the PMI include shortage of pediatric oncologists and nurses and high rate of abandonment of treatment...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905679/care-management-for-foreign-children-adolescents-young-adults-with-cancer-and-their-families
#10
Jérémie Gaudichon, Sandra Toscani, Sarah Cohen-Gogo, Juliette Saulpic, Aurore Surun, Oya Sakiroglu, François Doz, Jean Michon, Daniel Orbach
BACKGROUND: Little is known about care management for foreign patients in pediatric oncology in European centers. We aimed to describe care given to children, adolescents, and young adults who came to France for cancer treatment, and to determine whether their geographical origin had an influence on decision making. PROCEDURE: We conducted a monocentric retrospective study on all foreign patients aged 0-25 years and hospitalized for at least one night in Institut Curie (Paris, France) from 2009 to 2013...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905678/a-phase-i-ii-trial-of-at9283-a-selective-inhibitor-of-aurora-kinase-in-children-with-relapsed-or-refractory-acute-leukemia-challenges-to-run-early-phase-clinical-trials-for-children-with-leukemia
#11
B Vormoor, G J Veal, M J Griffin, A V Boddy, J Irving, L Minto, M Case, U Banerji, K E Swales, J R Tall, A S Moore, M Toguchi, G Acton, K Dyer, C Schwab, C J Harrison, J D Grainger, D Lancaster, P Kearns, D Hargrave, J Vormoor
Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory acute leukemia. The trial suffered from poor recruitment and terminated early, therefore failing to identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show clinical responses. Future trials should be based on robust preclinical data that provide an indication of which patients may benefit from the experimental agent, and recruitment should be improved through international collaborations and early combination with established treatment strategies...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905671/long-term-survivors-of-childhood-bone-and-soft-tissue-sarcomas-are-at-risk-of-hospitalization
#12
Cristian D Gonzalez, R Lor Randall, Jennifer Wright, Holly Spraker-Perlman, Jian Ying, Carol Sweeney, Ken R Smith, Anne C Kirchhoff
BACKGROUND: Childhood cancer survivors can have a high burden of chronic conditions related to cancer treatment, some of which are debilitating or potentially life-threatening. Much remains to be learned about late effects in bone and soft tissue sarcoma survivors. PROCEDURES: The Utah Cancer Registry was used to identify survivors of bone (N = 71) and soft tissue sarcomas (N = 98) who were diagnosed at ages 0-20 years between 1973 and 2007 and were alive at least 5 years after diagnosis...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27900832/bromodomain-and-extraterminal-protein-inhibitors-in-pediatrics-a-review-of-the-literature
#13
REVIEW
Irene Jiménez, André Baruchel, François Doz, Johannes Schulte
The last few years have seen the identification of pharmacologic approaches to target bromodomain and extraterminal (BET) proteins for cancer treatment. These proteins have an essential role in gene transcription regulation by binding acetylated lysine residues on histone tails, activating gene transcription. BET inhibitors have been tested in preclinical models including pediatric malignancies and several adult clinical trials are ongoing. Since the development of new drugs in pediatric cancer has long lagged behind programs for adults, the aim of this review is to show the importance of these therapies in pediatric malignancies to support their development in pediatric oncology/hematology...
November 30, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896933/feasibility-and-clinical-integration-of-molecular-profiling-for-target-identification-in-pediatric-solid-tumors
#14
Thomas Pincez, Nathalie Clément, Eve Lapouble, Gaëlle Pierron, Maud Kamal, Ivan Bieche, Virginie Bernard, Paul Fréneaux, Jean Michon, Daniel Orbach, Isabelle Aerts, Hélène Pacquement, Franck Bourdeaut, Irene Jiménez, Estelle Thébaud, Caroline Oudot, Cécile Vérité, Sophie Taque, Cormac Owens, François Doz, Christophe Le Tourneau, Olivier Delattre, Gudrun Schleiermacher
BACKGROUND: The role of tumor molecular profiling in directing targeted therapy utilization remains to be defined for pediatric tumors. We aimed to evaluate the feasibility of a sequencing and molecular biology tumor board (MBB) program, and its clinical impact on children with solid tumors. PROCEDURE: We report on a single-center MBB experience of 60 pediatric patients with a poor prognosis or relapsed/refractory solid tumors screened between October 2014 and November 2015...
November 29, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896944/quantifying-bias-in-survival-estimates-resulting-from-loss-to-follow-up-among-children-with-lymphoma-in-malawi
#15
Christopher C Stanley, Kate D Westmoreland, Salama Itimu, Ande Salima, Toon van der Gronde, Peter Wasswa, Idah Mtete, Mercy Butia, Nader K El-Mallawany, Satish Gopal
Pediatric lymphoma is common in sub-Saharan Africa, where survival estimates are often based on limited follow-up with incomplete retention, introducing potential for bias. We compared follow-up and overall survival (OS) between passive and active tracing within a prospective cohort of children with lymphoma in Malawi. Median follow-up times were 4.4 months (interquartile range [IQR] 2.0-9.4) and 10.8 months (IQR 6.2-20.6) in passive and active follow-up, respectively. Twelve-month overall survival (OS) was 69% (95% confidence interval [CI] 54-80) in passive and 44% (95% CI 34-54) in active follow-up...
November 28, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896941/patient-reported-neuropathic-pain-in-adolescent-and-young-adult-cancer-patients
#16
Melissa A Acquazzino, Eva C Igler, Mahua Dasgupta, Pippa Simpson, Meghen B Browning, Amanda M Brandow
BACKGROUND: Neuropathic pain, a known complication of cancer and its treatments, negatively impacts quality of life. There are limited data using screening tools to aid in the diagnosis of neuropathic pain in cancer patients. Our primary objective was to determine the proportion of adolescent and young adult cancer patients reporting neuropathic pain on a patient-completed, neuropathic pain screening tool. PROCEDURES: This prospective, cohort study enrolled patients 14-39 years of age who were receiving therapy for primary cancer diagnosis, cancer relapse, or had recently completed treatment...
November 28, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896936/health-related-quality-of-life-and-adherence-to-hydroxyurea-in-adolescents-and-young-adults-with-sickle-cell-disease
#17
Sherif M Badawy, Alexis A Thompson, Jin-Shei Lai, Frank J Penedo, Karen Rychlik, Robert I Liem
BACKGROUND: Complications related to sickle cell disease (SCD) result in significant declines in health-related quality of life (HRQOL). While hydroxyurea reduces SCD complications, adherence remains suboptimal. The study's objectives were to assess the feasibility of Internet-based electronic assessment of HRQOL in SCD clinic and to examine the relationship between HRQOL and hydroxyurea adherence in adolescents and young adults (AYAs) with SCD. PROCEDURE: A cross-sectional survey was administered on tablets to 34 AYAs (12-22 years old) in a SCD clinic from January through December 2015...
November 28, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896915/evaluation-of-maternal-and-perinatal-characteristics-on-childhood-lymphoma-risk-a-population-based-case-control-study
#18
Erin C Peckham-Gregory, Heather E Danysh, Austin L Brown, Olive Eckstein, Amanda Grimes, Rikhia Chakraborty, Joseph Lubega, Kenneth L McClain, Carl E Allen, Michael E Scheurer, Philip J Lupo
BACKGROUND: Lymphoma is one of the most common pediatric malignancies; however, there are few well-established risk factors. Therefore, we investigated if maternal and perinatal characteristics influenced the risk of childhood lymphoma. PROCEDURE: Information on cases (n = 374) diagnosed with lymphoma and born in Texas for the period 1995-2011 was obtained from the Texas Cancer Registry. Birth certificate controls were randomly selected at a ratio of 10 controls per 1 case for the same period of 1995-2011...
November 28, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27882658/access-to-clinical-trials-for-adolescents-with-soft-tissue-sarcomas-enrollment-in-european-pediatric-soft-tissue-sarcoma-study-group-epssg-protocols
#19
Andrea Ferrari, Annalisa Trama, Angela De Paoli, Christophe Bergeron, Johannes H M Merks, Meriel Jenney, Daniel Orbach, Julia C Chisholm, Soledad Gallego, Heidi Glosli, Gian Luca De Salvo, Laura Botta, Gemma Gatta, Gianni Bisogno
BACKGROUND: Adolescents with cancer are enrolled in clinical trials at far lower rates than children. This report compares the number of adolescents (15-19-year-olds) and children (0-14-year-olds) enrolled in the protocols of the European pediatric Soft tissue sarcoma Study Group (EpSSG) with the number of cases expected to occur. METHODS: The observed-to-expected (O/E) ratio was detected in the EpSSG countries contributing most of the cases, that is, Italy, France, Spain, the Netherlands, United Kingdom, and Ireland...
November 24, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27878966/risk-adapted-stratification-for-optimally-intensive-treatment-assignment-of-pediatric-patients-with-non-hodgkin-lymphoma-is-an-effective-strategy-in-developing-countries
#20
Asim F Belgaumi, Mohammed Anas, Khawar S Siddiqui, Mohammed F Akhter, Amani Al-Kofide
BACKGROUND: Pediatric patients with non-Hodgkin lymphoma (NHL) in developing countries (DCs) present with greater tumor load even at lower stages and with comorbidities that impact therapy delivery. This causes toxic mortality with "standard" intensive protocols or recurrences with "gentler" treatment. OBJECTIVES: We developed and evaluated a risk stratification schema that guides intensity of therapy. DESIGN/METHODS: Sixty-nine patients were prospectively assigned to five risk groups (A-E; n = 6, 15, 16, 15, and 17) following staging and treated with protocols of risk-stratified intensity...
November 23, 2016: Pediatric Blood & Cancer
journal
journal
20217
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"